Business
Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel
VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel\n\n\n\n VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the appointments of\n \n Mr. Yevgeniy Meshcherekov\n \n and\n \n Dr. David Kideckel\n \n to the Company’s board of directors (the “\n \n Board\n \n ”), subject to receiving approval from the TSX Venture Exchange (“\n \n TSXV\n \n ”). The Company also announces that Michael Liggett has retired from the Board. Subject to TSXV approval, Mr. Meshcherekov will replace Mr. Liggett as the chair of the audit committee of the Board.\n \n\n Mr. Yevgeniy Meshcherekov is a seasoned financial executive and Chartered Professional Accountant, bringing over 20 years of post-designation experience across public practice, private enterprise, and public markets. His extensive background spans a range of industries, including fintech, blockchain, and family office investment management.\n \n\n Mr. Meshcherekov’s career includes executive leadership roles, notably as CFO of TAAL, a publicly listed Canadian blockchain infrastructure company, and financial oversight across complex, multi-jurisdictional corporate structures. He is recognized for his expertise in financial governance, cross-border tax strategy, and regulatory compliance, as well as for building high-performing finance teams and implementing customized accounting systems.\n \n\n Dr. David M. Kideckel, Ph.D., M.B.A, is the Founder and Principal of Kideckel Advisory Group Inc., where he provides fractional CFO, CBO, and capital markets services to public (TSX, Nasdaq) and private corporations. He is also a Partner at Siskos & Associates, focusing on finance and accounting-specific strategies for public and private issuers within the Life Sciences sector.\n \n\n Dr. Kideckel is a Life Sciences and Financial Services industry veteran, combining nearly 20 years of industry, advisory, and capital markets experience, most recently serving as Managing Director, Head of Life Sciences & Senior Institutional Equity Research Analyst at ATB Capital Markets. David’s industry experience spa...